Concepedia

Author

Anna Maria Fink

University Hospital CologneORCID

Also Known As

A Fink, A M Fink, A. Fink, A. M Fink, A. M. Fink, A.-M. Fink, A.M. Fink, Anna Fink, Anna M Fink, Anna M. Fink

131

Publications

4.3K

Citations

23

H-Index

23

Concepts

All Affiliations

University Hospital CologneUniversität UlmUniversity of CologneUniversity Hospital UlmMünchen Klinik Schwabing
AM

About

Anna Maria Fink is an author at University Hospital Cologne specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

1.2K

2

Health Sciences

3

3

90

3

Immunology

3

3

116

4

Pathology

2

2

46

5

Cell Biology

1

1

1K

Anna Maria Fink

×

29

Publications

4K

Citations

21

H-Index

YearCitations

Mutations driving CLL and their evolution in progression and relapse

Dan A. Landau, Eugen Tausch, Amaro Taylor‐Weiner,

Nature

2015

1K

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink,

Blood

2015

693

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,

Blood

2014

502

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

Sebastian Böttcher, Matthias Ritgen, Kirsten Fischer,

Journal of Clinical Oncology

2012

445

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group

Gábor Kovács, Sandra Robrecht, Anna Maria Fink,

Journal of Clinical Oncology

2016

170

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Michael Hallek, Guenter Fingerle-Rowson, Anna Maria Fink,

Blood

2008

134

A Context-based Chatbot Surpasses Radiologists and Generic ChatGPT in Following the ACR Appropriateness Guidelines

Alexander Rau, Stephan Rau, Daniela Zoeller,

Radiology

2023

133

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara Eichhorst, Anna Maria Fink, Raymonde Busch,

Blood

2014

117

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

Kirsten Fischer, Stephan Stilgenbauer, Carmen D. Schweighofer,

Blood

2008

99

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

Othman Al‐Sawaf, Can Zhang, Hyun Yong Jin,

Nature Communications

2023

85

Page 1